Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: Potential of ceramide as a metastasis-suppressor lipid

Oncogene

Volumn 35, Issue 21, 2016, Pages 2801-2812

  Kitatani, K ^a   Usui, T ^a   Sriraman, S K ^b   Toyoshima, M ^a   Ishibashi, M ^a   Shigeta, S ^a   Nagase, S ^c   Sakamoto, M ^a   Ogiso, H ^d   Okazaki, T ^d   Hannun, Y A ^e   Torchilin, V P ^b   Yaegashi, N ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NORTHEASTERN UNIVERSITY   (United States)

^c YAMAGATA UNIVERSITY   (Japan)

^d KANAZAWA MEDICAL UNIVERSITY   (Japan)

^e STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FUMONISIN B1; GLUCOSYLCERAMIDE; LIPOSOME; MIGLUSTAT; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 4 PHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE 3 KINASE BETA; PHOSPHOPROTEIN PHOSPHATASE; RHODAMINE B; SMALL INTERFERING RNA; SPHINGOMYELIN; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL MOTILITY; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVE SITE; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; THERAPY EFFECT; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANIMAL; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CERAMIDES; FEMALE; HUMANS; MICE; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE;

EID: 84941710478     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.330     Document Type: Article

References (70)

1. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010; 177: 1053-1064.
2. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013; 19: 961-968.
3. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005; 5: 355-366.
4. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006; 7: 925-934.
5. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005; 96: 379-386.
6. Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci. 2013; 34: 283-289.
7. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996; 84: 359-369.
8. Nurnberg A, Kitzing T, Grosse R. Nucleating actin for invasion. Nat Rev Cancer. 2011; 11: 177-187.
9. Meyer AS, Hughes-Alford SK, Kay JE, Castillo A, Wells A, Gertler FB, et al. 2D protrusion but not motility predicts growth factor-induced cancer cell migration in 3D collagen. J Cell Biol. 2012; 197: 721-729.
10. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science. 1996; 274: 1855-1859.
11. Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal. 2008; 20: 1010-1018.
12. Kitatani K, Sheldon K, Anelli V, Jenkins RW, Sun Y, Grabowski GA, et al. Acid betaglucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. J Biol Chem. 2009; 284: 12979-12988.
13. Clarke CJ, Truong TG, Hannun YA. Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J Biol Chem. 2007; 282: 1384-1396.
14. Garzotto M, White-Jones M, Jiang Y, Ehleiter D, Liao WC, Haimovitz-Friedman A, et al. 12-O-Tetradecanoylphorbol-13-Acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res. 1998; 58: 2260-2264.
15. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008; 9: 139-150.
16. Park JW, Park WJ, Futerman AH. Ceramide synthases as potential targets for therapeutic intervention in human diseases. Biochim Biophys Acta. 2014; 1841: 671-681.
17. Ogretmen B, Pettus BJ, Rossi MJ, Wood R, Usta J, Szulc Z, et al. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem. 2002; 277: 12960-12969.
18. Takeda S, Mitsutake S, Tsuji K, Igarashi Y. Apoptosis occurs via the ceramide recycling pathway in human HaCaT keratinocytes. J Biochem. 2006; 139: 255-262.
19. Kitatani K, Idkowiak-Baldys J, Bielawski J, Taha TA, Jenkins RW, Senkal CE, et al. Protein kinase C-induced activation of a ceramide/protein phosphatase 1 pathway leading to dephosphorylation of p38 MAPK. J Biol Chem. 2006; 281: 36793-36802.
20. Kitatani K, Idkowiak-Baldys J, Hannun YA. Mechanism of inhibition of sequestration of protein kinase C alpha/betaII by ceramide. Roles of ceramide-Activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C alpha/betaII on threonine 638/641. J Biol Chem. 2007; 282: 20647-20656.
21. Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2013; 13: 51-65.
22. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res. 2005; 11: 3465-3474.
23. Stover T, Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J Pharmacol Exp Ther. 2003; 307: 468-475.
24. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007; 67: 4843-4850.
25. Boddapati SV, D'Souza GG, Erdogan S, Torchilin VP, Weissig V. Organelle-Targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 2008; 8: 2559-2563.
26. Koshkaryev A, Piroyan A, Torchilin VP. Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Biol Ther. 2012; 13: 50-60.
27. Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res. 2008; 14: 3571-3581.
28. Edmond V, Dufour F, Poiroux G, Shoji K, Malleter M, Fouque A, et al. Downregulation of ceramide synthase-6 during epithelial-To-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. Oncogene. 2014; 34: 996-1005.
29. Xue G, Hemmings BA. PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst. 2013; 105: 393-404.
30. Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013; 10: 143-153.
31. Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9: 415-428.
32. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999; 21: 99-102.
33. Stratford S, Hoehn KL, Liu F, Summers SA. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol Chem. 2004; 279: 36608-36615.
34. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 2009; 26: 273-287.
35. Ip CK, Cheung AN, Ngan HY, Wong AS. p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene. 2011; 30: 2420-2432.
36. Yoshizaki H, Mochizuki N, Gotoh Y, Matsuda M. Akt-PDK1 complex mediates epidermal growth factor-induced membrane protrusion through Ral activation. Mol Biol Cell. 2007; 18: 119-128.
37. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998; 67: 481-507.
38. Nitta M, Katabuchi H, Ohtake H, Tashiro H, Yamaizumi M, Okamura H. Characterization and tumorigenicity of human ovarian surface epithelial cells immortalized by SV40 large T antigen. Gynecol Oncol. 2001; 81: 10-17.
39. Wang E, Norred WP, Bacon CW, Riley RT, Merrill Jr AH. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. J Biol Chem. 1991; 266: 14486-14490.
40. Wijesinghe DS, Massiello A, Subramanian P, Szulc Z, Bielawska A, Chalfant CE. Substrate specificity of human ceramide kinase. J Lipid Res. 2005; 46: 2706-2716.
41. Niikura H, Sasano H, Sato S, Yajima A. Expression of epidermal growth factorrelated proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol. 1997; 16: 60-68.
42. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer. 1996; 73: 301-306.
43. Zhou HY, Pon YL, Wong AS. Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-Activated protein kinase. Endocrinology. 2007; 148: 5195-5208.
44. Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, Kawai K, et al. Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell. 2005; 9: 389-402.
45. Zhou H, Summers SA, Birnbaum MJ, Pittman RN. Inhibition of Akt kinase by cellpermeable ceramide and its implications for ceramide-induced apoptosis. J Biol Chem. 1998; 273: 16568-16575.
46. Dobrowsky RT, Hannun YA. Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem. 1992; 267: 5048-5051.
47. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004; 4: 604-616.
48. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J. 1988; 256: 283-290.
49. Ishihara H, Martin BL, Brautigan DL, Karaki H, Ozaki H, Kato Y, et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun. 1989; 159: 871-877.
50. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008; 133: 403-414.
51. Aschrafi A, Franzen R, Shabahang S, Fabbro D, Pfeilschifter J, Huwiler A. Ceramide induces translocation of protein kinase C-Alpha to the Golgi compartment of human embryonic kidney cells by interacting with the C2 domain. Biochim Biophys Acta. 2003; 1634: 30-39.
52. Huwiler A, Fabbro D, Pfeilschifter J. Selective ceramide binding to protein kinase C-Alpha and -delta isoenzymes in renal mesangial cells. Biochemistry. 1998; 37: 14556-14562.
53. Huwiler A, Johansen B, Skarstad A, Pfeilschifter J. Ceramide binds to the CaLB domain of cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release. Faseb J. 2001; 15: 7-9.
54. Arcaro A, Volinia S, Zvelebil MJ, Stein R, Watton SJ, Layton MJ, et al. Downward J, Waterfield MD. Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J Biol Chem. 1998; 273: 33082-33090.
55. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005; 5: 921-929.
56. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4: 145-160.
57. Sun Y, Fox T, Adhikary G, Kester M, Pearlman E. Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. J Leukoc Biol. 2008; 83: 1512-1521.
58. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28: 15-33.
59. Maffucci T, Cooke FT, Foster FM, Traer CJ, Fry MJ, Falasca M. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol. 2005; 169: 789-799.
60. Pua TL, Wang FQ, Fishman DA. Roles of LPA in ovarian cancer development and progression. Future oncology. 2009; 5: 1659-1673.
61. Boller D, Doepfner KT, De Laurentiis A, Guerreiro AS, Marinov M, Shalaby T, et al. Targeting PI3KC2beta impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours. Anticancer Res. 2012; 32: 3015-3027.
62. Muller G, Ayoub M, Storz P, Rennecke J, Fabbro D, Pfizenmaier K. PKC zeta is a molecular switch in signal transduction of TNF-Alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J. 1995; 14: 1961-1969.
63. Chalfant CE, Szulc Z, Roddy P, Bielawska A, Hannun YA. The structural requirements for ceramide activation of serine-Threonine protein phosphatases. J Lipid Res. 2004; 45: 496-506.
64. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2 A activity and signaling. FASEB J. 2009; 23: 751-763.
65. Huwiler A, Brunner J, Hummel R, Vervoordeldonk M, Stabel S, van den Bosch H, et al. Ceramide-binding and activation defines protein kinase c-Raf as a ceramideactivated protein kinase. Proc Natl Acad Sci USA. 1996; 93: 6959-6963.
66. Yin X, Zafrullah M, Lee H, Haimovitz-Friedman A, Fuks Z, Kolesnick R. A ceramidebinding C1 domain mediates kinase suppressor of ras membrane translocation. Cell Physiol Biochem. 2009; 24: 219-230.
67. Calzolari A, Oliviero I, Deaglio S, Mariani G, Biffoni M, Sposi NM, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis. 2007; 39: 82-91.
68. Karahatay S, Thomas K, Koybasi S, Senkal CE, Elojeimy S, Liu X, et al. Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett. 2007; 256: 101-111.
69. Ogiso H, Taniguchi M, Araya S, Aoki S, Wardhani LO, Yamashita Y, et al. Comparative analysis of biological sphingolipids with glycerophospholipids and diacylglycerol by LC-MS/MS. Metabolites. 2014; 4: 98-114.
70. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37: 911-917.